Biote Corp. (Class A) (BTMD) exhibits 45.0% gross margins and 85.0% return on invested capital within Health Care (Medicinal Chemicals and Botanical Products), balanced against a 2.9x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 18.5% operating margin and 85.0% ROIC, outpacing sector cost of capital.
ROIC: 85.0% // GM: 45.0%YoY revenue trajectory of -2.5% paired with 2.80% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -2.5% // FCF YLD: 2.80%Altman Z-Score of 2.50 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.50 // F-SCORE: 6/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 2.9xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $1.17 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medicinal Chemicals and Botanical Products require continuous execution to defend 14.1% net margins.
NET MARGIN: 14.1% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BTMD & activate live FRED threshold breach alerts.